Dendritic Cell Maturation Cocktail for Anti-Tumor Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dendritic cell-based cancer therapies lack an effective method for maturing dendritic cells ex vivo to induce a robust anti-tumor immune response, particularly in a manner that is universally applicable across various cancer types and infectious diseases.
Innovation Solution
A dendritic cell maturation cocktail comprising a Toll-like receptor-3 agonist (Ampligen), interleukin-1β, interferons (IFN-α and IFN-γ), CD40L, and a Toll-like receptor-7/8 agonist (R848) is used to mature dendritic cells ex vivo, enhancing their antigen-presenting capabilities and inducing a potent anti-tumor T-helper response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If dendritic cells are cultured with a single maturation agent, then the maturation process is simple, but the anti-tumor immune response is insufficient
Solution Approach 1:
The patent combines multiple maturation agents (TLR-3 agonist, TLR-7/8 agonist, IL-1β, interferons, and CD40L) into a single cocktail formulation. This merging of multiple agents works synergistically to achieve robust dendritic cell maturation and potent anti-tumor immune responses, resolving the contradiction between process simplicity and treatment efficacy.
Solution Approach 2:
The maturation cocktail functions as a composite biological formulation where multiple cytokines and agonists work together. Each component contributes specific functions: TLR agonists stimulate pattern recognition receptors, IL-1β promotes inflammation, interferons enhance antigen presentation, and CD40L provides co-stimulation. This composite approach achieves reliable anti-tumor immunity that single agents cannot accomplish alone.
2Reliability
If a complex maturation cocktail is used, then the anti-tumor immune response is enhanced, but the manufacturing process becomes more complex
Solution Approach 1:
Multiple maturation agents are merged into a single cocktail that can be prepared and applied in one step. This consolidation reduces the number of separate processing steps while maintaining the synergistic effects of all components, thereby enhancing immune response without proportionally increasing manufacturing complexity.
Solution Approach 2:
The maturation cocktail is designed as a universal formulation applicable to various cancer types and infectious diseases. The same cocktail composition can be used across different therapeutic contexts, standardizing the manufacturing process and reducing complexity despite the multiple agents involved.
3Manufacturing precision
If dendritic cells are matured ex vivo with multiple agents, then the maturation phenotype is optimized, but the production time increases
Solution Approach 1:
The maturation cocktail enables continuous and sustained stimulation of dendritic cells through multiple simultaneous pathways. The agents work continuously during the culture period to drive maturation, ensuring that the full maturation phenotype is achieved within the standard 6-7 day ex vivo production window without requiring extended culture times.
Solution Approach 2:
The cocktail components are prepared and combined in advance before being applied to the dendritic cells. This preliminary preparation allows the maturation process to begin immediately upon cell addition, maximizing the efficiency of the ex vivo production timeline while achieving optimal maturation phenotype.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The maturation cocktail effectively produces mature dendritic cells that express high levels of Th1 effector cytokines, such as IL-12p70 and IFN-γ, capable of activating CD8+ T-cells and eliciting a significant anti-tumor immune response, demonstrating efficacy across multiple cancer types and infectious diseases.
Implementation Method 1
a method to mature the dendritic cells (DCs) ex vivo using a dendritic cell maturation cocktail comprising a Toll-like receptor (TLR)-3 agonist (Ampligen), interleukin (IL)-1β (IL-1β), interferons (IFN)-α, IFN-γ, CD40L and a TLR-7/8 agonist (R848)
Implementation Method 2
interleukin (IL)-1β (IL-1β), interferons (IFN)-α, IFN-γ, CD40L
Implementation Method 3
CD40L
Data Source
AI summary
The present invention relates to in vitro methods of producing mature dendritic cells, a dendritic cell maturation cocktail, a method of producing mature antigen presenting dendritic cells in vitro, methods of manufacturing vaccines containing mature dendritic cells, antigen-presenting mature dendritic cells produced according to the methods described, vaccines containing the mature antigen-presenting dendritic cells and methods of treatment and used of mature antigen-presenting cells of the invention.